Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Pradaxa
Pradaxa 20 mg coated granules Pradaxa 30 mg coated granules Pradaxa 40 mg coated granules Pradaxa 50 mg coated granules Pradaxa 110 mg coated granules Pradaxa 150 mg coated granules · Abschnitt 4.5 · PDF-Seite 121
HOS-118907 · Präparat HOS-094855
Selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake
inhibitors (SNRIs)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 4500fbb1421be734520861bad41a7291e03a16a6b9632885a341d674dc8f2e68 · Zeichen 11493–11609 im Abschnitt
Wechselwirkungen · Effentora
Effentora 100 micrograms buccal tablets Effentora 200 micrograms buccal tablets Effentora 400 micrograms buccal tablets Effentora 600 micrograms buccal tablets Effentora 800 micrograms buccal tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-209220 · Präparat HOS-154273
Serotoninergic agents
Co-administration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake
Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase
Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening
condition. Effentora is not recommended for use in patients who have received MAOIs within 14 days
because severe and unpredictable potentiation by MAOIs has been reported with opioid analgesics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:58:00Z · SHA-256 b4a304bd9d2ca3f423d95be522ff20307f46a2ce762379e94c21a56805a240f8 · Passage 1585dba6923b023b097416350e62c87fc13e537cf7ba5656383bf2bd9e92aea2 · Zeichen 2328–2835 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-119744 · Präparat HOS-095005
13
IMMUNOSUPPRESSANTS
Cyclosporin Not studied. Etravirine is expected to decrease Co-administration with
Sirolimus plasma concentrations of cyclosporine, systemic
Tacrolimus sirolimus and tacrolimus. immunosuppressants should
be done with caution because
plasma concentrations of
cyclosporin, sirolimus and
tacrolimus may be affected
when co-administered with
INTELENCE.
NARCOTIC ANALGESICS
Methadone R(-) methadone No changes in methadone
individual dose ranging AUC ↔ 1.06 (0.99-1.13) dosage were required based
from 60 mg to 130 mg Cmin ↔ 1.10 (1.02-1.19) on clinical status during or
once daily Cmax ↔ 1.02 (0.96-1.09) after the period of
S(+) methadone INTELENCE
AUC ↔ 0.89 (0.82-0.96) co-administration.
Cmin ↔ 0.89 (0.81-0.98)
Cmax ↔ 0.89 (0.83-0.97)
etravirine
AUC ↔a
Cmin ↔a
Cmax ↔a
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS
Sildenafil 50 mg single sildenafil Concomitant use of PDE-5
dose AUC ↓ 0.43 (0.36-0.51) inhibitors with INTELENCE
Tadalafil Cmin ND may require dose adjustment
Vardenafil Cmax ↓ 0.55 (0.40-0.75) of the PDE-5 inhibitor to
N-desmethyl-sildenafil attain the desired clinical
AUC ↓ 0.59 (0.52-0.68) effect.
Cmin ND
Cmax ↓ 0.75 (0.59-0.96)
PLATELET AGGREGGATION INHIBITORS
Clopidogrel In vitro data show that etravirine has inhibitory As a precaution it is
properties on CYP2C19. It is therefore possible recommended that
that etravirine may inhibit the metabolism of concomitant use of etravirine
clopidogrel to its active metabolite by such and clopidogrel should be
inhibition of CYP2C19 in vivo. The clinical discouraged.
relevance of this interaction has not been
demonstrated.
PROTON PUMP INHIBITORS
Omeprazole etravirine INTELENCE can be
40 mg once daily AUC ↑ 1.41 (1.22-1.62) co-administered with proton
Cmin ND pump inhibitors without dose
Cmax ↑ 1.17 (0.96-1.43) adjustments.
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
Paroxetine paroxetine INTELENCE can be
20 mg once daily AUC ↔ 1.03 (0.90-1.18) co-administered with
Cmin ↓ 0.87 (0.75-1.02) paroxetine without dose
Cmax ↔ 1.06 (0.95-1.20) adjustments.
etravirine
AUC ↔ 1.01 (0.93-1.10)
Cmin ↔ 1.07 (0.98-1.17)
Cmax ↔ 1.05 (0.96-1.15)
a
Comparison based on historic control.
b
Study was conducted with tenofovir disoproxil fumarate 300 mg once daily
Note: In drug-drug interaction studies, different formulations and/or doses of etravirine were used which led to similar
exposures and, therefore, interactions relevant for one formulation are relevant for the other.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) tadalafil (HOS-086316) methadone (HOS-086198) serotonin (HOS-085477) clopidogrel (HOS-087927) tacrolimus (HOS-085202) tenofovir disoproxil fumarate (HOS-110471) sirolimus (HOS-085172) sildenafil (HOS-086162) cyclosporine (HOS-084512) omeprazole (HOS-085912) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage f67f8a9ca44e51616bf8034fedb121fdf73f499dc5e74eb944693ba3f0dbe471 · Zeichen 29319–34348 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7
HOS-120556 · Präparat HOS-095157
Coadministration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake
Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase
Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening
condition.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage bad3795141e723888d2a1125a94e0c124a847288d1c71d06c5d8caa5f0790e4a · Zeichen 116–415 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms nasal spray, solution in single-dose container Instanyl 100 micrograms nasal spray, solution in single-dose container Instanyl 200 micrograms nasal spray, solution in single-dose container · Abschnitt 4.5 · PDF-Seite 20
HOS-120581 · Präparat HOS-095157
Coadministration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake
Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase
Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening
condition.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage bad3795141e723888d2a1125a94e0c124a847288d1c71d06c5d8caa5f0790e4a · Zeichen 116–415 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 33
HOS-120604 · Präparat HOS-095157
Coadministration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake
Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase
Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening
condition.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage bad3795141e723888d2a1125a94e0c124a847288d1c71d06c5d8caa5f0790e4a · Zeichen 116–415 im Abschnitt
Wechselwirkungen · Firdapse (previously Zenas)
FIRDAPSE 10 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-210246 · Präparat HOS-154477
Medicinal products known to lower the epileptic threshold
The concomitant use of amifampridine and substances known to lower the epileptic threshold may
lead to an increased risk of seizures. The decision to administer proconvulsant or epileptic-threshold
lowering substances concomitantly should be carefully considered in the light of the severity of the
associated risks. These substances include most anti-depressants (tricyclic antidepressants, selective
serotonin uptake inhibitors), neuroleptics (phenothiazines and butyrophenones), mefloquine,
bupropion and tramadol (see sections 4.4 and 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) lead (HOS-085592) serotonin (HOS-085477) mefloquine (HOS-113850) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-05-25T11:00:00Z · SHA-256 92cbbf47b9125cbf72b4c63d78ca50f05a820bbcbe9f450c757171186f057752 · Passage f62afcf92eea0df25ca44cb5864e21dd6960517614004477c8d3727cb9318191 · Zeichen 2275–2877 im Abschnitt
Wechselwirkungen · Sildenafil Teva
Sildenafil Teva 25 mg film-coated tablets Sildenafil Teva 50 mg film-coated tablets Sildenafil Teva 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-210781 · Präparat HOS-154587
Although specific interaction studies were not conducted for all medicinal products, population
pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics
when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors
(such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related
diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium
channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as
rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin
antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at
steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in
62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. Therefore, concomitant
administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in
plasma concentrations of sildenafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) calcium (HOS-085615) serotonin (HOS-085477) potassium (HOS-086929) bosentan (HOS-086291) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-07-04T14:29:00Z · SHA-256 0b432e138830c0aeb116ef3ec7bfb1d55513ba6e91690f196dc9b46d7cffe7bc · Passage ff031b81b0c99a94fcaa56bc3b110e0f54f206bf85a99290bc93652b329e3366 · Zeichen 2987–4092 im Abschnitt
Wechselwirkungen · Vizarsin
Vizarsin 25 mg film-coated tablets Vizarsin 50 mg film-coated tablets Vizarsin 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-210876 · Präparat HOS-154603
Although specific interaction studies were not conducted for all medicinal products, population
pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics
when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors
(such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related
diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium
channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as
rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin
antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at
steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in
62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. Therefore, concomitant
administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in
plasma concentrations of sildenafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) calcium (HOS-085615) serotonin (HOS-085477) potassium (HOS-086929) bosentan (HOS-086291) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-24T16:29:00Z · SHA-256 2f808d91fd284718f9fd3477080213020dbb8a472917304bcbc8075d93a4c6f6 · Passage ff031b81b0c99a94fcaa56bc3b110e0f54f206bf85a99290bc93652b329e3366 · Zeichen 2982–4087 im Abschnitt
Wechselwirkungen · Vizarsin
Vizarsin 25 mg orodispersible tablets Vizarsin 50 mg orodispersible tablets Vizarsin 100 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 19
HOS-210920 · Präparat HOS-154603
Although specific interaction studies were not conducted for all medicinal products, population
pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics
when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors
(such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related
diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium
channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as
rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin
antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at
steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in
62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. Therefore, concomitant
administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in
plasma concentrations of sildenafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) calcium (HOS-085615) serotonin (HOS-085477) potassium (HOS-086929) bosentan (HOS-086291) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-24T16:29:00Z · SHA-256 2f808d91fd284718f9fd3477080213020dbb8a472917304bcbc8075d93a4c6f6 · Passage ff031b81b0c99a94fcaa56bc3b110e0f54f206bf85a99290bc93652b329e3366 · Zeichen 2983–4088 im Abschnitt
Wechselwirkungen · Sildenafil ratiopharm
Sildenafil ratiopharm 25 mg film-coated tablets Sildenafil ratiopharm 50 mg film-coated tablets Sildenafil ratiopharm 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-121678 · Präparat HOS-095413
Although specific interaction studies were not conducted for all medicinal products, population
pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics
when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors
(such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related
diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium
channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as
rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin
antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at
steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in
62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. Therefore, concomitant
administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in
plasma concentrations of sildenafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) calcium (HOS-085615) serotonin (HOS-085477) potassium (HOS-086929) bosentan (HOS-086291) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-06-24T11:00:00Z · SHA-256 c808d2606faf49a55ff479538c23c7b32973eab6a82cf87d69b7ee7085cb369e · Passage ff031b81b0c99a94fcaa56bc3b110e0f54f206bf85a99290bc93652b329e3366 · Zeichen 2979–4084 im Abschnitt
Wechselwirkungen · Sildenafil Actavis
Sildenafil Actavis 25 mg film-coated tablets Sildenafil Actavis 50 mg film-coated tablets Sildenafil Actavis 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211712 · Präparat HOS-154739
Although specific interaction studies were not conducted for all medicinal products, population
pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics
when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors
(such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related
diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium
channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as
rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin
antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at
steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in
62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. Therefore, concomitant
administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in
plasma concentrations of sildenafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) calcium (HOS-085615) serotonin (HOS-085477) potassium (HOS-086929) bosentan (HOS-086291) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-11-13T17:59:00Z · SHA-256 8d339cf63d7199374f2ece12de82d79c2afadc784f0e022556816c15588f8759 · Passage ff031b81b0c99a94fcaa56bc3b110e0f54f206bf85a99290bc93652b329e3366 · Zeichen 2980–4085 im Abschnitt
Wechselwirkungen · PecFent
PecFent 100 micrograms/spray nasal spray, solution PecFent 400 micrograms/spray nasal spray, solution · Abschnitt 4.5 · PDF-Seite 8
HOS-212299 · Präparat HOS-154864
Serotoninergic medicinal products:
Coadministration of fentanyl with a serotoninergic medicinal product, such as a Selective Serotonin
Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a
Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially
life-threatening condition.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T09:30:00Z · SHA-256 6c66e20c8a5497199e4a93d57ee169d120fab4ca07ded4b5af9add0ded3852e4 · Passage 0d58cbdc6c39acfd13b1ac70fd25b33598ad58fe389df70f069271d48ca0ec89 · Zeichen 1965–2311 im Abschnitt
Wechselwirkungen · Methylthioninium chloride Proveblue
Methylthioninium chloride Proveblue 5 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-213653 · Präparat HOS-155158
Methylthioninium chloride should be avoided in patients receiving medicinal products that enhance
serotonergic transmission because of the potential for serious CNS reactions, including potentially fatal
serotonin syndrome. These include SSRIs (selective serotonin reuptake inhibitors), bupropion,
buspirone, clomipramine, mirtazapine, and venlafaxine. Opioids, for example, tramadol, fentanyl,
pethidine, and dextromethorphan, may also increase the risk of developing serotonin syndrome, when
used in combination with methylthioninium chloride. If the intravenous use of methylthioninium
chloride cannot be avoided in patients treated with serotonergic medicinal products, the lowest possible
dose should be chosen and the patient observed closely for central nervous system (CNS) effects for up
to 4 hours after administration (see sections 4.4 and 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) venlafaxine (HOS-086573) serotonin (HOS-085477) clomipramine (HOS-085906) mirtazapine (HOS-144406) buspirone (HOS-086325) fentanyl (HOS-086196) dextromethorphan (HOS-109265) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T17:19:00Z · SHA-256 19c53bf82f55a8d25e4c6a9ce5fce20575d1af796cef659dc721231268971317 · Passage 5d108e81ebe37e06fa7a97ec420e29ae2832486a9d97d04b89c9ed6e3c9daf74 · Zeichen 0–856 im Abschnitt
Wechselwirkungen · Sancuso
SANCUSO 3.1 mg/24 hours transdermal patch · Abschnitt 4.5 · PDF-Seite 4
HOS-214212 · Präparat HOS-155296
For serotonergic medicinal products (e.g. SSRIs and SNRIs, buprenorphine, opiods or other
serotonergic medicinal products), there have been reports of serotonin syndrome following
concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs and
SNRIs).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): buprenorphine (HOS-086193) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-02T02:00:00Z · SHA-256 af505a5d494cc3abf921a1b2459b86fb6afe3c2a44e28fa38d7503f0c05d03b5 · Passage 10d451106b733154ea25eb51502266b0acdc2555fba214fc315e7b1d089dc459 · Zeichen 0–287 im Abschnitt
Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-215301 · Präparat HOS-155418
15
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with
(dose) Cmax, Cmin with confidence efavirenz
intervals if availablea
(mechanism)
Vigabatrin/efavirenz Interaction not studied. Clinically No dose adjustment is necessary
Gabapentin/efavirenz significant interactions are not for any of these medicinal
expected since vigabatrin and products.
gabapentin are exclusively eliminated
unchanged in the urine and are
unlikely to compete for the same
metabolic enzymes and elimination
pathways as efavirenz.
ANTIDEPRESSANTS
Selective Serotonin Reuptake Inhibitors (SSRIs)
Sertraline/efavirenz Sertraline: Sertraline dose increases should
(50 mg once daily/600 mg once AUC: ↓ 39% (↓ 27 to ↓ 50) be guided by clinical response.
daily) Cmax: ↓ 29% (↓ 15 to ↓ 40) No dose adjustment is necessary
Cmin: ↓ 46% (↓ 31 to ↓ 58) for efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vigabatrin (HOS-115599) gabapentin (HOS-090745) serotonin (HOS-085477) sertraline (HOS-086247)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage e27e9ae72c851e114aa5c2ee81c0dc43bac54fa507bcdb52f0b715be7d40555f · Zeichen 43513–44993 im Abschnitt
Wechselwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-125738 · Präparat HOS-096139
Antidepressants
The concomitant use of safinamide and fluoxetine or fluvoxamine should be avoided (see section 4.4),
this precaution is based on the occurrence of serious adverse reactions (e.g. serotonin syndrome),
although rare, that have occurred when SSRIs and dextromethorphan have been used with MAO
inhibitors. If necessary, the concomitant use of these medicinal products should be at the lowest
effective dose. A washout period corresponding to 5 half-lives of the SSRI used previously should be
considered prior to initiating treatment with safinamide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477) fluoxetine (HOS-085946) dextromethorphan (HOS-109265) fluvoxamine (HOS-085908)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage f4061cfe5a7a1207267305d859ad69bf34aaef1ff75367b475248fa2de87afe7 · Zeichen 1327–1889 im Abschnitt
Wechselwirkungen · Xadago
Xadago 50 mg film-coated tablets Xadago 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-125739 · Präparat HOS-096139
4
Serious adverse reactions have been reported with the concomitant use of selective serotonin reuptake
inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic/tetracyclic
antidepressants and MAO inhibitors (see section 4.4). In view of the selective and reversible MAO-B
inhibitory activity of safinamide, antidepressants may be administered but used at the lowest doses
necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T12:57:00Z · SHA-256 48b01ba5b1179c2ba1e43605dbb52f4115246d6aa2dd76fd1814d41eff2382ed · Passage b79f8d740563d58e8e70a9e0d21a8597812e0c8ddd235c2febd314c425dd97ff · Zeichen 1947–2358 im Abschnitt
Wechselwirkungen · Latuda
Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-128657 · Präparat HOS-096607
5
Latuda should be used cautiously when co-administered with other serotonergic agents, such as
buprenorphine/opioids, MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin
norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin
syndrome, a potentially life-threatening condition, is increased (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norepinephrine (HOS-090547) buprenorphine (HOS-086193) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:17:00Z · SHA-256 1b4eb934eea6c777e082db5accb51f11c854318bf5d2d82b61249264a6b6a684 · Passage 70c3f5fb66e37b06683588c4d4e5694ba7fdc260389391cf815875e0918ca96a · Zeichen 575–952 im Abschnitt
Wechselwirkungen · Brintellix
Brintellix 5 mg film-coated tablets Brintellix 10 mg film-coated tablets Brintellix 15 mg film-coated tablets Brintellix 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-128719 · Präparat HOS-096615
Irreversible non-selective MAOIs
Due to the risk of serotonin syndrome, vortioxetine is contraindicated in any combination with
irreversible non-selective MAOIs. Vortioxetine must not be initiated for at least 14 days after
discontinuation of treatment with an irreversible non-selective MAOI. Vortioxetine must be
discontinued for at least 14 days before starting treatment with an irreversible non-selective MAOI
(see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T08:59:00Z · SHA-256 39c9a9149ac76ca0fbe73df123a7c9f5de7dcd96ddbd144fa863659dff9cbf06 · Passage c25cdbe9fc9c410a346739b0cacff05160ed48c87f20b548f93cf9a1a27144a2 · Zeichen 227–660 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.